Digestive Diseases and Sciences

, Volume 60, Issue 11, pp 3465–3472 | Cite as

Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir

  • Tse-Ling FongEmail author
  • Andy Tien
  • Kahee J. Jo
  • Danny Chu
  • Eddie Cheung
  • Edward A. Mena
  • Quang-Quoc Phan
  • Andy S. Yu
  • Wafa Mohammed
  • Andrew Velasco
  • Vinh-Huy LeDuc
  • Nickolas Nguyen
  • Steven-Bui Han
  • Mimi Chang
  • Ho S. Bae
  • Yong-Won Cho
  • Myron J. Tong
  • Stewart L. Cooper
Original Article



Loss of HBeAg and development of anti-HBe (seroconversion) is seen as a milestone and endpoint in the treatment of HBeAg-positive patients with chronic hepatitis B (CHB). Among patients treated with nucleos(t)ide analogs (NA), recurrent viremia is common after discontinuation of therapy. Entecavir (ETV) and tenofovir (TDF) are highly potent NA. The durability of virological response and HBeAg seroconversion in patients treated with these agents is not well studied.


We retrospectively studied the outcomes of 54 HBeAg-positive CHB patients who were treated with either ETV (n = 30) or TDF (23) or both (n = 1) that achieved virological response and underwent seroconversion and consolidation therapy before cessation of treatment.


Only 4 (7 %) patients had sustained virological, serological, and biochemical remission. Thirteen patients (24 %) continued to have HBV DNA levels below 2000 IU/mL and normal alanine aminotransferase activity (ALT). Thirty-seven patients (69 %) developed HBV DNA >2000 IU/mL, with 20 having elevated ALT. Among these 37 patients, 23 (62 %) remained HBeAg negative/anti-HBe positive, 12 (32 %) became HBeAg positive, and 2 (5 %) were HBeAg and anti-HBe negative. Duration of consolidation therapy did not correlate with low versus high level of virological relapse.


Durability of HBeAg seroconversion associated with ETV or TDF was not superior to that reported in patients treated with less potent NA. Our results, aggregated with others, suggest HBeAg seroconversion should not be considered as a treatment endpoint for most HBeAg-positive patients treated with NA. Future updates of treatment guidelines should reconsider HBeAg seroconversion as an endpoint to therapy.


Remission Relapse Seroreversion 



We thank Dr. Dat Nghiem for reviewing this manuscript and for his thoughtful comments and suggestions. Authors received the grant support from Gilead Sciences and Daughters of Charity Foundation.

Compliance with Ethical Standards

Conflict of interest

Tse-Ling Fong and Myron J Tong: Gilead Sciences; Speaker Bureau, Advisory Board, Research Funding. BMS; Speaker Bureau, Advisory Board, Research Funding. Andy Tien, Kahee J. Jo, Wafa Mohammed, Andrew Velasco, Vinh-Huy LeDuc, Nickolas Nguyen, Yong-Won Cho and Stewart L. Cooper: No industry relationships or conflicts of interest. Danny Chu, Eddie Cheung, Edward A. Mena, Quang-Quoc Phan, Andy Yu, Steven-Bui Han, Ho S. Bae: Gilead Sciences; Speaker Bureau, Advisory Board. BMS; Speaker Bureau, Advisory Board. Mimi Chang: Gilead Sciences; Speaker Bureau. BMS; Speaker Bureau.


  1. 1.
    Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology. 1986;6:167–172.CrossRefPubMedGoogle Scholar
  2. 2.
    Hui CK, Leung N, Shek TW, et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology. 2007;46:690–698.CrossRefPubMedGoogle Scholar
  3. 3.
    Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010;55:2727–2734. doi: 10.1007/s10620-010-1179-4.CrossRefPubMedGoogle Scholar
  4. 4.
    Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–1527.CrossRefPubMedGoogle Scholar
  5. 5.
    Kuo L-F, Lee C-M, Hung C-H, et al. High risk of hepatitis B virus reactivation in nucleos(t)e analogue-induced hepatitis B e antigen seroconverters older than 40 years. Dig Dis Sci. 2014;59:2580–2587.CrossRefPubMedGoogle Scholar
  6. 6.
    Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003;37:748–755.CrossRefPubMedGoogle Scholar
  7. 7.
    Poynard T, Hou J-H, Chutaputti A, Manns M, Naoumov N. Sustained durability of HBeAg seroconversion in chronic hepatitis B patients after treatment with telbivudine. J Hepatol. 2008;48:S268.Google Scholar
  8. 8.
    Song B-C, Suh DJ, Lee HC, Chung Y-H, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32:803–806.CrossRefPubMedGoogle Scholar
  9. 9.
    Jo K, Dodge JL, Wadley A, Wakil AE, Baron JL, Cooper S. HBeAg seroconversion is lower in Asian versus non-Asian patients during treatment of chronic hepatitis B with tenofovir or entecavir. Hepatology. 2013;58:669A.CrossRefGoogle Scholar
  10. 10.
    Lee CM, Ong G-Y, Lin S-N, et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol. 2002;37:669–674.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang L, Liu F, Li X-Y, Wang J-B, Zhang Z-H, Wang Y-Z. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepat. 2010;17:298–304.CrossRefPubMedGoogle Scholar
  12. 12.
    Song BC, Cui XJ, Cho YK, et al. New scoring system for predicting relapse after lamivudine-induced hepatitis B e-antigen loss in chronic hepatitis B patients. Hepatol Res. 2009;39:1064–1071.CrossRefPubMedGoogle Scholar
  13. 13.
    Fung J, Lai CL, Tanaka Y, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation versus continuation of treatment after HBeAg seroconversion. Am J Gastroenterol. 2009;104:1940–1946.CrossRefPubMedGoogle Scholar
  14. 14.
    Jin YJ, Kim KM, Yoo DJ, et al. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. Virol J. 2012;9:239.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Chien R-N, Yeh C-T, Tsai S-L, Chu C-M, Liaw Y-F. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38:1267–1273.CrossRefPubMedGoogle Scholar
  16. 16.
    Byun KS, Kwon OS, Kim JH, et al. Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. J Gastroenterol Hepatol. 2005;20:1838–1842.CrossRefPubMedGoogle Scholar
  17. 17.
    Kuo YH, Chen CH, Wang JH, et al. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol. 2010;45:75–81.CrossRefPubMedGoogle Scholar
  18. 18.
    Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology. 2010;51:415–421.CrossRefPubMedGoogle Scholar
  19. 19.
    Reijnders JGP, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology. 2010;139:491–498.CrossRefPubMedGoogle Scholar
  20. 20.
    Chaung KT, Ha NB, Trinh HN, et al. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastrol. 2012;46:865–870.CrossRefGoogle Scholar
  21. 21.
    Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.CrossRefPubMedGoogle Scholar
  22. 22.
    Ahn J, Lee HM, Lim J, et al. Entecavir safety and effectiveness in a natural cohort of chronic hepatitis B patients in the United States. The ENUMERATE study. Hepatology. 2014;60:1100A.CrossRefGoogle Scholar
  23. 23.
    Lok ASF, McMahon B. Chronic hepatitis B. Hepatology. 2007;45:507–539.CrossRefPubMedGoogle Scholar
  24. 24.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.CrossRefGoogle Scholar
  25. 25.
    Liaw YF, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–561.CrossRefPubMedGoogle Scholar
  26. 26.
    Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437–1444.CrossRefPubMedGoogle Scholar
  28. 28.
    Ridruejo E, Marciano S, Galdane O, et al. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir. J Viral Hepat. 2014;21:590–596.CrossRefPubMedGoogle Scholar
  29. 29.
    Song MJ, Song DS, Kim HY, et al. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol. 2012;18:6277–6283.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Publicover J, Goodsell A, Nishimura S, et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest. 2011;121:1154–1162.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531.CrossRefPubMedGoogle Scholar
  32. 32.
    Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537–1547.CrossRefPubMedGoogle Scholar
  33. 33.
    Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893.CrossRefPubMedGoogle Scholar
  34. 34.
    Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.CrossRefPubMedGoogle Scholar
  35. 35.
    Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107.CrossRefPubMedGoogle Scholar
  36. 36.
    Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014;147:143–151.CrossRefPubMedGoogle Scholar
  37. 37.
    Chen CJ, Yang HI, Su J, et al. REVEAL-HBV Study Group Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.CrossRefPubMedGoogle Scholar
  38. 38.
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) study group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686.CrossRefPubMedGoogle Scholar
  39. 39.
    Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013;62:760–765.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Tse-Ling Fong
    • 1
    • 2
    Email author
  • Andy Tien
    • 1
  • Kahee J. Jo
    • 3
  • Danny Chu
    • 4
  • Eddie Cheung
    • 5
    • 6
  • Edward A. Mena
    • 7
  • Quang-Quoc Phan
    • 8
  • Andy S. Yu
    • 9
  • Wafa Mohammed
    • 1
  • Andrew Velasco
    • 1
  • Vinh-Huy LeDuc
    • 1
  • Nickolas Nguyen
    • 1
  • Steven-Bui Han
    • 10
  • Mimi Chang
    • 1
  • Ho S. Bae
    • 1
  • Yong-Won Cho
    • 1
  • Myron J. Tong
    • 7
  • Stewart L. Cooper
    • 3
  1. 1.Asian Pacific Liver CenterSaint Vincent Medical CenterLos AngelesUSA
  2. 2.Division of Gastrointestinal and Liver Diseases, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  3. 3.Liver Disease and Transplant ProgramCalifornia Pacific Medical CenterSan FranciscoUSA
  4. 4.Private PracticeNew YorkUSA
  5. 5.Division of GastroenterologyUniversity of California DavisDavisUSA
  6. 6.Private PracticeOaklandUSA
  7. 7.Liver CenterHuntington Research InstitutePasadenaUSA
  8. 8.Private PracticeFountain ValleyUSA
  9. 9.Private PracticeSan JoseUSA
  10. 10.Division of Gastroenterology, Geffen School of MedicineUniversity of California Los AngelesLos AngelesUSA

Personalised recommendations